Vanc Pharmaceuticals Launches First OTC Product in British Columbia
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 12/07/15 -- Vanc Pharmaceuticals Inc. ("Vanc" or the "Company") (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has commercialized its first OTC products in British Columbia: Cortivera™ and Cortivera Plus™ (Natural Product Number (NPN): 80037898) for a wide range of minor skin irritations, allergic reactions and eczema.
Both products are formulated with aloe vera and Cortivera™ contains 0.5% hydrocortisone and Cortivera Plus™ contains 1% hydrocortisone. Both are available in cream and ointment form in order to meet the specific needs of patients. The combination of aloe vera and hydrocortisone offers therapeutic benefits for skin irritations such as minor burns, allergic itch, insect bite itch, sun burn itch, eczema in addition to acting as an anti-inflammatory.
"We are excited to have launched the first product from our OTC portfolio and are confident in its ability to compete with the leading products in the category," said Arun Nayyar, CEO of Vanc. "In addition to our generic drug business which is seeing sales ramp up we have received positive feedback from pharmacy customers on Cortivera™ and Cortivera Plus™."
On behalf of:
Vanc Pharmaceuticals Inc.
Arun Nayyar, CEO
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC''s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Vanc Pharmaceuticals Inc.
Arun Nayyar
CEO
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.12.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 1402708
Anzahl Zeichen: 2979
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Drugs
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 240 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vanc Pharmaceuticals Launches First OTC Product in British Columbia
"
steht unter der journalistisch-redaktionellen Verantwortung von
Vanc Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
